
BE in a statement on Thursday said it will leverage its experience to develop and commercialise the vaccine candidate, which currently is produced using a proven yeast-based expression technology.
from Healthcare/Biotech-Industry-Economic Times https://ift.tt/33Uk9Qz
via
IFTTT
0 comments:
Post a Comment